Review article: Thiazolidinediones and heart failure
- PMID: 20368206
- DOI: 10.1177/1479164109338772
Review article: Thiazolidinediones and heart failure
Abstract
DM is an independent risk factor for the development of HF and its presence confers an adverse prognosis for those already diagnosed with HF.TZDs are potent insulin-sensitisers associated with a number of beneficial cardiovascular effects. However,TZDs increase renal sodium and water reabsorption, leading to fluid retention and overt signs of HF in patients with diabetes. Rosiglitazone has also been associated with an increased risk of myocardial infarction and cardiovascular mortality. However, pioglitazone may have macrovascular benefits. The majority of data on the cardiovascular safety of TZDs are based on non-cardovascular outcome trials and meta-analyses. Concerns regarding the risk of HF and cardiovascular safety of TZDs have led to restrictions on their use in patients with HF. This review addresses the latest evidence for HF with each of the TZD drugs currently available and reflects on the current guidelines regarding their prescription in at-risk patients.
Similar articles
-
Thiazolidinediones in type 2 diabetes: a cardiology perspective.Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Ann Pharmacother. 2008. PMID: 18698014 Review.
-
Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11. Cerebrovasc Dis. 2013. PMID: 24029780
-
Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008.Cardiovasc Drugs Ther. 2008 Jun;22(3):233-40. doi: 10.1007/s10557-008-6093-z. Epub 2008 Mar 29. Cardiovasc Drugs Ther. 2008. PMID: 18373186 Review.
-
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Clin Ther. 2011. PMID: 22118894
-
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?Diab Vasc Dis Res. 2005 May;2(2):61-6. doi: 10.3132/dvdr.2005.010. Diab Vasc Dis Res. 2005. PMID: 16305060 Review.
Cited by
-
Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?Drug Saf. 2015 Jan;38(1):17-32. doi: 10.1007/s40264-014-0247-7. Drug Saf. 2015. PMID: 25481812 Review.
-
Expression of retinol binding protein 4 and nuclear factor-κB in diabetic rats with atherosclerosis and the intervention effect of pioglitazone.Exp Ther Med. 2016 Aug;12(2):1000-1006. doi: 10.3892/etm.2016.3340. Epub 2016 May 16. Exp Ther Med. 2016. PMID: 27446311 Free PMC article.
-
Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.Drugs. 2010 Dec 3;70(17):2229-45. doi: 10.2165/11585220-000000000-00000. Drugs. 2010. PMID: 21080740 Review.
-
Discovery of Novel Insulin Sensitizers: Promising Approaches and _targets.PPAR Res. 2017;2017:8360919. doi: 10.1155/2017/8360919. Epub 2017 Jun 4. PPAR Res. 2017. PMID: 28659972 Free PMC article. Review.
-
Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.Curr Hypertens Rep. 2014 Aug;16(8):455. doi: 10.1007/s11906-014-0455-7. Curr Hypertens Rep. 2014. PMID: 24908134 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
